BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 109 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $32,404 | -77.3% | 12,808 | -40.3% | 0.00% | – |
Q2 2023 | $142,790 | -55.7% | 21,440 | +24.0% | 0.00% | – |
Q1 2023 | $322,000 | +129217.3% | 17,291 | +49.1% | 0.00% | – |
Q4 2022 | $249 | -99.8% | 11,595 | +9.5% | 0.00% | – |
Q3 2022 | $126,000 | -8.0% | 10,589 | +2.0% | 0.00% | – |
Q2 2022 | $137,000 | -51.8% | 10,378 | -23.7% | 0.00% | – |
Q1 2022 | $284,000 | +19.3% | 13,606 | +15.9% | 0.00% | – |
Q4 2021 | $238,000 | -28.3% | 11,736 | +7.1% | 0.00% | – |
Q3 2021 | $332,000 | +20.3% | 10,953 | +15.5% | 0.00% | – |
Q2 2021 | $276,000 | -22.0% | 9,481 | +15.5% | 0.00% | – |
Q1 2021 | $354,000 | +32.1% | 8,212 | +41.4% | 0.00% | – |
Q4 2020 | $268,000 | +42.6% | 5,807 | +32.7% | 0.00% | – |
Q3 2020 | $188,000 | -0.5% | 4,375 | +22.7% | 0.00% | – |
Q2 2020 | $189,000 | +278.0% | 3,565 | +60.4% | 0.00% | – |
Q1 2020 | $50,000 | -62.7% | 2,222 | -75.7% | 0.00% | – |
Q4 2019 | $134,000 | +857.1% | 9,144 | +362.5% | 0.00% | – |
Q3 2019 | $14,000 | -22.2% | 1,977 | +19.4% | 0.00% | – |
Q2 2019 | $18,000 | – | 1,656 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Knoll Capital Management, LLC | 60,000 | $151,800 | 0.16% |
XTX Topco Ltd | 33,605 | $85,021 | 0.02% |
Beacon Pointe Advisors, LLC | 301,735 | $763,390 | 0.01% |
AllSquare Wealth Management LLC | 4,527 | $11,453 | 0.01% |
Virtus ETF Advisers LLC | 4,646 | $11,754 | 0.01% |
Y-Intercept (Hong Kong) Ltd | 27,553 | $69,709 | 0.01% |
SeaCrest Wealth Management, LLC | 16,550 | $41,872 | 0.01% |
Hennion & Walsh Asset Management, Inc. | 33,940 | $85,868 | 0.01% |
Cutler Group LLC / CA | 4,000 | $50 | 0.01% |
Capital Investment Advisory Services, LLC | 17,991 | $45,517 | 0.00% |